Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Merck Sharp & Dohme is the lead sponsor of 201 current clinical trials in our USA, UK, China, Ireland, India and EU (CTIS) registers. 107 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pembrolizumab, Paclitaxel and Sacituzumab tirumotecan. The most-studied condition is Healthy.

Company profiles on this site (news, sites, medicines, approvals): Merck & Co. (US) →MSD Ireland (IE) →

ClinicalTrials.gov trials by status

Recruiting10756%
Active, closed8344%

Trials by phase

Phase 38947%
Phase 23921%
Phase 1/23116%
Phase 12513%
Phase 2/353%
Observational11%

Clinical trials sponsored by Merck Sharp & Dohme

190 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) NCT06780085 · Carcinoma, Non-Small-Cell Lung Drugs: Ifinatamab Deruxtecan, Raludotatug Deruxtecan	Phase 2	Recruiting	2025-05	USA
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors Drugs: Calderasib, Carboplatin, Cetuximab	Phase 1	Recruiting	2021-12	USA, China
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 · Ovarian Neoplasms, Ovarian Cancer Drugs: Bevacizumab, Sacituzumab tirumotecan	Phase 3	Recruiting	2026-02	Ireland, UK, USA
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729 · Non-small Cell Lung Cancer Drugs: Calderasib, Pembrolizumab	Phase 3	Recruiting	2024-05	UK, USA, India, China
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374 · Triple-Negative Breast Cancer Drugs: Capecitabine, Pembrolizumab, Sacituzumab tirumotecan	Phase 3	Recruiting	2024-06	Ireland, UK, USA
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) NCT06596694 · Gastrointestinal Cancer Drug: Patritumab Deruxtecan	Phase 1/2	Recruiting	2024-11	USA, China
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) NCT07049926 · Renal Cell Carcinoma Drugs: Belzutifan, Zanzalintinib	Phase 1/2	Recruiting	2025-07	UK, USA
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) NCT06637423 · Non-Muscle Invasive Bladder Cancer Drug: Sacituzumab tirumotecan	Phase 1/2	Recruiting	2024-12	UK, USA
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 · Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Drug: MK-1045	Phase 1/2	Recruiting	2026-05	UK, USA, China
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies Drugs: ) Berahyaluronidase alfa, Lenvatinib, Olaparib	Phase 3	Recruiting	2018-08	Ireland, UK, USA, China
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495 · Carcinoma, Renal Cell Drugs: Belzutifan, Zanzalintinib	Phase 3	Recruiting	2026-04	UK, USA
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) NCT04924075 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease Drug: Belzutifan	Phase 2	Recruiting	2021-08	UK, USA, China
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: Acetaminophen, Bevacizumab, Dexamethasone	Phase 3	Recruiting	2025-04	Ireland, UK, USA
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) NCT05714085 · Heart Failure, Left Ventricular Systolic Dysfunction Drug: Vericiguat	Phase 2/3	Recruiting	2023-05	Ireland, UK, USA
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272 · Malignant Neoplasm Drug: Patritumab Deruxtecan	Phase 1/2	Recruiting	2025-05	UK, USA
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 3	Recruiting	2025-05	Ireland, UK, USA, China
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms Drugs: Abiraterone acetate, Dexamethasone, Enzalutamide	Phase 3	Recruiting	2023-12	Ireland, UK, USA, China
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) NCT07247110 · Malignant Neoplasm Drugs: Cetuximab, Pembrolizumab	Phase 1	Recruiting	2025-12	USA
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) NCT06430801 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Tulisokibart	Phase 3	Recruiting	2024-06	Ireland, UK, USA, China
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostatic Neoplasms Drugs: Docetaxel, Ifinatamab Deruxtecan, Prednisone	Phase 3	Recruiting	2025-05	Ireland, UK, USA, China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 3	Recruiting	2024-10	Ireland, UK, USA, China
A Study of V132 in Healthy Older Participants (V132-001) NCT07712575 · Healthy Drugs: 20-valent pneumococcal conjugate vaccine, Capvaxive	Phase 1	Recruiting	2026-08	USA
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · ClinicalTrials.gov ↗ · Cervical Cancer Drugs: Bevacizumab, Carboplatin, Cisplatin	Phase 3	Recruiting	2026-01	Ireland, UK, USA, India
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176 · ClinicalTrials.gov ↗ · Breast Neoplasms Drugs: Capecitabine, Liposomal doxorubicin, Nab-paclitaxel	Phase 3	Recruiting	2024-04	Ireland, UK, USA, India
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) NCT07227402 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma Drugs: Belzutifan, Cabozantinib, Zanzalintinib	Phase 3	Recruiting	2025-11	Ireland, UK, USA, China
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, NSCLC Drugs: Carboplatin, Nab-paclitaxel, Paclitaxel	Phase 3	Recruiting	2024-06	Ireland, UK, USA, China
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624 · ClinicalTrials.gov ↗ · Prostate Cancer Metastatic Drugs: Abiraterone acetate, Dexamethasone, Enzalutamide	Phase 3	Recruiting	2023-12	Ireland, UK, USA, China
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) NCT07513376 · Non-small Cell Lung Cancer	Phase 3	Recruiting	2026-05	UK, USA, China
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272 · ClinicalTrials.gov ↗ · Castration-Resistant Prostatic Cancer, Metastasis Drugs: Abiraterone, Docetaxel, Enzalutamide	Phase 1/2	Recruiting	2025-07	Ireland, UK, USA
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) NCT06890884 · ClinicalTrials.gov ↗ · Lymphoma, Large B-Cell, Diffuse Drugs: Cyclophosphamide, Doxorubicin, Polatuzumab Vedotin	Phase 2	Recruiting	2025-04	Ireland, UK, USA
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893 · ClinicalTrials.gov ↗ · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma Drug: Nemtabrutinib	Phase 2	Recruiting	2021-04	Ireland, UK, USA, China
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Castration-Resistant Drugs: Cabazitaxel, Dexamethasone, Docetaxel	Phase 1/2	Recruiting	2024-05	Ireland, UK, USA, China
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) NCT06780137 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drugs: Durvalumab, Gocatamig, Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2025-02	UK, USA, China
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: ) Berahyaluronidase alfa, Calderasib, Carboplatin	Phase 3	Recruiting	2025-10	UK, USA, China
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) NCT07058077 · ClinicalTrials.gov ↗ · Heterozygous Familial Hypercholesterolemia (HeFH) Drug: Enlicitide Decanoate	Phase 2/3	Recruiting	2025-08	UK, USA, China
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · ClinicalTrials.gov ↗ · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms Drugs: Capecitabine, Carboplatin, Cyclophosphamide	Phase 3	Recruiting	2025-06	UK, USA, India, China
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017 · ClinicalTrials.gov ↗ · DLBCL, Diffuse Large B-Cell Lymphoma Drugs: Bendamustine, G-Csf, Gemcitabine	Phase 2/3	Recruiting	2022-01	UK, USA, China
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668 · ClinicalTrials.gov ↗ · Melanoma, Lymphoma, Solid Tumor Drug: Pembrolizumab	Phase 1/2	Recruiting	2015-03	UK, USA
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · Diffuse Large B-Cell Lymphoma Drugs: Cyclophosphamide, Doxorubicin, Methylprednisolone	Phase 3	Recruiting	2025-01	USA, China
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) NCT07300267 · Pneumococcal Infection Drug: 20-valent pneumococcal conjugate vaccine	Phase 1	Recruiting	2026-01	USA
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms Drugs: Carboplatin, Gemcitabine, Nab-paclitaxel	Phase 3	Recruiting	2025-03	UK, USA, China
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) NCT07033494 · ClinicalTrials.gov ↗ · Early Alzheimer's Disease	Phase 2	Recruiting	2025-07	UK, USA
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) NCT07463183 · ClinicalTrials.gov ↗ · Colitis Ulcerative, Ulcerative Colitis	Phase 2	Recruiting	2026-03	UK, USA
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) NCT06961006 · Malignant Melanoma Drugs: Intismeran autogene, Pembrolizumab	Phase 2	Recruiting	2025-05	USA
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) NCT06651281 · ClinicalTrials.gov ↗ · Crohn Disease, Colitis, Ulcerative Drug: Tulisokibart	Phase 3	Recruiting	2024-11	UK, USA
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974 · Malignant Neoplasm Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2026-07	USA
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) NCT06170788 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drugs: Pembrolizumab, Sacituzumab tirumotecan	Phase 3	Recruiting	2023-12	UK, USA, China
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Rectal Adenocarcinoma Drugs: Bevacizumab, Bevacizumab biosimilar, Calderasib	Phase 3	Recruiting	2025-07	UK, USA, China
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) NCT05562830 · ClinicalTrials.gov ↗ · Urothelial Carcinoma Drugs: MK-3120, Pembrolizumab, Zilovertamab vedotin	Phase 1/2	Recruiting	2022-11	UK, USA
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) NCT06136559 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Drugs: Acalabrutinib, Ibrutinib, Nemtabrutinib	Phase 3	Recruiting	2023-12	UK, USA, China
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) NCT07286149 · Lung Neoplasm Malignant Drugs: Cetuximab, MK-1084, Patritumab Deruxtecan	Phase 1/2	Recruiting	2026-04	USA, China
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) NCT07486960 · Psoriatic Arthritis Drug: Tulisokibart	Phase 2	Recruiting	2026-04	USA
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111 · ClinicalTrials.gov ↗ · Neoplasm Malignant Drugs: Calderasib, Cetuximab	Phase 2	Recruiting	2025-12	UK, USA, China
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851 · ClinicalTrials.gov ↗ · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Drugs: Nemtabrutinib, Rituximab, Venetoclax	Phase 3	Recruiting	2023-08	UK, USA
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) NCT04165798 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Observational	Recruiting	2019-12	USA
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) NCT06833073 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ Drug: Intismeran autogene	Phase 2	Recruiting	2025-03	UK, USA
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) NCT07252739 · ClinicalTrials.gov ↗ · Malignant Neoplasm Drugs: Cetuximab, MK-1084, Pembrolizumab	Phase 2	Recruiting	2025-12	USA, China
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) NCT05587712 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension Drug: Sotatercept	Phase 2	Recruiting	2023-01	UK, USA
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) NCT07218029 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension Drug: Sotatercept	Phase 3	Recruiting	2021-05	UK, USA
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) NCT07232602 · ClinicalTrials.gov ↗ · Bladder Cancer Drugs: MK-3120, Pembrolizumab	Phase 1/2	Recruiting	2026-02	UK, USA
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) NCT07133633 · ClinicalTrials.gov ↗ · Radiographic Axial Spondyloarthritis Drug: Tulisokibart	Phase 2	Recruiting	2025-09	UK, USA, China
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) NCT06667700 · ClinicalTrials.gov ↗ · Coronavirus Disease (COVID-19) Drug: Molnupiravir	Phase 3	Recruiting	2024-12	UK, USA
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · ClinicalTrials.gov ↗ · Follicular Lymphoma Drugs: Bendamustine, Cyclophosphamide, Doxorubicin Hydrochloride	Phase 2/3	Recruiting	2026-06	USA, China
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 3	Recruiting	2024-04	UK, USA, China
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 · ClinicalTrials.gov ↗ · Von Hippel-Lindau Disease, Malignant Neoplasms Drugs: Belzutifan, Cabozantinib, Lenvatinib	Phase 3	Recruiting	2026-03	UK, USA
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) NCT07554339 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Calderasib, Durvalumab	Phase 3	Recruiting	2026-06	USA, China
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) NCT04665037 · ClinicalTrials.gov ↗ · Invasive Fungal Infection Drug: Posaconazole	Phase 2	Recruiting	2022-02	USA
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) NCT07199465 · ClinicalTrials.gov ↗ · Cytomegalovirus Prophylaxis Drug: Letermovir	Phase 1	Recruiting	2026-03	USA
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) NCT06686394 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer Drugs: Patritumab Deruxtecan, Pertuzumab, Trastuzumab	Phase 1/2	Recruiting	2025-02	UK, USA
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807 · ClinicalTrials.gov ↗ · Breast Neoplasms Drugs: Abraxane, Capecitabine, Liposomal doxorubicin	Phase 3	Recruiting	2025-07	UK, USA, China
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) NCT06843447 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent Drugs: Bevacizumab, Carboplatin, Gemcitabine	Phase 1/2	Recruiting	2025-04	UK, USA
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295 · ClinicalTrials.gov ↗ · Bladder Cancer Drugs: Docetaxel, Paclitaxel, Sacituzumab tirumotecan	Phase 3	Recruiting	2026-04	UK, USA, China
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) NCT06979596 · ClinicalTrials.gov ↗ · Malignant Neoplasm Drugs: Exemestane, Fulvestrant, Letrozole	Phase 2	Recruiting	2025-08	UK, USA
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) NCT06395103 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma Drug: Zilovertamab vedotin	Phase 1/2	Recruiting	2024-08	UK, USA
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 · ClinicalTrials.gov ↗ · Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis Drug: Bomedemstat	Phase 3	Recruiting	2024-05	UK, USA
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · ClinicalTrials.gov ↗ · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer Drugs: Cisplatin, Fluorouracil, Ivonescimab	Phase 1/2	Recruiting	2024-06	UK, USA, China
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Calderasib, Pembrolizumab Formulated with Berahyaluronidase Alfa	Phase 3	Recruiting	2026-03	UK, China
A Study of V118E in Healthy Participants (V118E-003) NCT07168915 · ClinicalTrials.gov ↗ · Healthy Drug: 20-valent pneumococcal conjugate vaccine	Phase 1	Recruiting	2025-10	USA
A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) NCT07734610 · ClinicalTrials.gov ↗ · Severe Renal Impairment, Healthy Drug: Nemtabrutinib	Phase 1	Recruiting	2026-09	USA
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · ClinicalTrials.gov ↗ · Squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Intismeran autogene, Nab-paclitaxel	Phase 2	Recruiting	2025-12	USA, China
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). NCT06623409 · ClinicalTrials.gov ↗ · Healthy Drug: GARDASIL9	Phase 1	Recruiting	2024-11	USA
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) NCT06655883 · ClinicalTrials.gov ↗ · Insomnia	Phase 3	Recruiting	2025-10	USA
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) NCT06445972 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms Drugs: Paclitaxel, Patritumab Deruxtecan, Ramucirumab	Phase 1/2	Recruiting	2024-08	USA, China
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer Drugs: Capecitabine, Carboplatin, Cyclophosphamide	Phase 2	Recruiting	2025-03	USA
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms Drugs: Capecitabine, Ivonescimab, Leucovorin	Phase 1/2	Recruiting	2024-09	USA, China
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Nab-paclitaxel, Paclitaxel	Phase 2	Recruiting	2025-03	USA
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: Carboplatin, Ifinatamab Deruxtecan, MK-4830	Phase 1/2	Recruiting	2019-12	USA
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) NCT07705555 · ClinicalTrials.gov ↗ · Diabetic Retinopathy, Macular Edema Drug: Aflibercept	Phase 3	Recruiting	2026-08	USA
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) NCT07697625 · ClinicalTrials.gov ↗ · Healthy Drug: Diltiazem	Phase 1	Recruiting	2026-07	USA
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Ifinatamab Deruxtecan, Ivonescimab, Leucovorin	Phase 1/2	Recruiting	2025-07	USA, China
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) NCT07595263 · ClinicalTrials.gov ↗ · Healthy Drug: Methadone	Phase 1	Recruiting	2026-08	USA
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151 · ClinicalTrials.gov ↗ · Oesophageal Squamous Cell Carcinoma Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2026-03	USA, China
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001). NCT06655324 · ClinicalTrials.gov ↗ · Healthy	Phase 1	Recruiting	2024-12	USA
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) NCT07600749 · ClinicalTrials.gov ↗ · Malignant Neoplasm	Phase 1	Recruiting	2026-06	USA
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) NCT04375800 · ClinicalTrials.gov ↗ · Human Immunodeficiency Virus (HIV) Infection Drug: 2 NRTIs	Phase 2	Recruiting	2021-02	USA
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) NCT06780098 · ClinicalTrials.gov ↗ · Lung Neoplasm Drugs: Docetaxel, Ifinatamab Deruxtecan, R-DXd	Phase 2	Recruiting	2025-05	USA, China
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) NCT06818643 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Malignant Neoplasm Drug: MK-3120	Phase 1/2	Recruiting	2025-03	USA, China
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · ClinicalTrials.gov ↗ · Lung Neoplasm Malignant Drugs: Acetaminophen, Carboplatin, Cisplatin	Phase 2	Recruiting	2025-03	USA
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) NCT07266831 · ClinicalTrials.gov ↗ · Human Immunodeficiency Virus Type 1 (HIV-1) Infection Drug: BIC/FTC/TAF	Phase 2/3	Recruiting	2025-12	USA
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) NCT07743151 · ClinicalTrials.gov ↗ · Healthy	Phase 1	Recruiting	2026-09	USA

Showing the 100 most recently updated of 190 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Merck Sharp & Dohme in the EU trials register (CTIS)

11 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Merck Sharp & Dohme as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease 2024-518296-56-00 · CTIS ↗ · Digestive System Diseases Drug: Tulisokibart	Phase 3	Ongoing	Ireland + 20 more
A clinical trial of MK-1824 in healthy participants (MK-1824-002) 2026-527518-22-00 · Cardiovascular Diseases	Phase 1	Authorised	Belgium
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis 2025-523479-49-00 · CTIS ↗ · Digestive System Diseases	Phase 2	Ongoing	Italy, Greece, Netherlands + 3 more
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014) 2025-522643-18-00 · CTIS ↗ · Neoplasms Drugs: Intismeran autogene, Pembrolizumab Formulated with Berahyaluronidase Alfa	Phase 3	Ongoing	Greece, Poland, Italy + 5 more
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) 2025-522038-29-00 · CTIS ↗ · Neoplasms Drugs: Durvalumab, MK-1084	Phase 3	Ongoing	Italy, Netherlands, France + 4 more
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) 2025-522267-15-00 · CTIS ↗ · Neoplasms Drugs: Blinatumomab, MK-1045, Tocilizumab	Phase 3	Ongoing	Greece, Netherlands, Sweden + 4 more
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors 2025-522339-32-00 · CTIS ↗ · Neoplasms Drug: Ifinatamab Deruxtecan	Phase 1	Ongoing	France, Spain, Sweden + 8 more
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F 2026-525213-31-00 · CTIS ↗ · Neoplasms Drug: Ifinatamab Deruxtecan	Phase 2	Ongoing	Czechia, Germany, France + 1 more
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations 2024-512248-47-00 · CTIS ↗ · Neoplasms Drugs: Cetuximab, MK-1084, Patritumab Deruxtecan	Phase 1	Ongoing	Italy, Germany, Greece + 3 more
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer 2025-520467-40-00 · CTIS ↗ · Neoplasms Drug: MK-3120	Phase 1	Ongoing	Belgium, Greece, Austria + 5 more
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012). 2024-517232-22-00 · CTIS ↗ · Neoplasms Drugs: Bevacizumab, Calcium folinate, Calcium levofolinate	Phase 3	Ongoing	Poland, Spain, Netherlands + 6 more

Drugs in Merck Sharp & Dohme trials

141 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 101 more in the trial list above.

Conditions in Merck Sharp & Dohme trials

160 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in USA	180	105
Clinical trials in UK	113	60
Clinical trials in China	89	48
Clinical trials in Ireland	35	19
Clinical trials in India	5	4
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Healthy

Sponsor	Trials
Eli Lilly and Company	15
University of Electronic Science and Technology of China	10
Olly, PBC	5
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences	4
Boehringer Ingelheim	3
dōTERRA International	3
Qualia Life Sciences	2
Clinical Nutrition Research Center, Illinois Institute of Technology	2
Keymed Biosciences	2
Shenyang Sunshine Pharmaceutical	2

Sponsors with the most current trials registered for this condition.

Questions about Merck Sharp & Dohme trials

How many clinical trials does Merck Sharp & Dohme sponsor?

Merck Sharp & Dohme is the lead sponsor of 190 current trials on ClinicalTrials.gov in our USA, UK, China, Ireland and India registers, and 11 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Merck Sharp & Dohme trials recruiting?

Yes. 107 of its 190 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Merck Sharp & Dohme testing?

Its current trials name 141 drugs and biologicals as interventions. The most frequent are Pembrolizumab (66), Paclitaxel (28), Sacituzumab tirumotecan (28), Carboplatin (23) and Cisplatin (17). The number in brackets is how many of its trials name each drug.

Does Merck Sharp & Dohme have clinical trials in Ireland?

Yes. 35 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Merck Sharp & Dohme clinical trials